These observations thus merit comprehensive consideration with regard to the renal hemodynamic action of SGLT2 inhibitors and their background medications when SGLT2 inhibitors are used in patients with DM and hypertension. The gene discussed is SLC5A2; the disease is diabetes mellitus.